Keytruda
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial
Keytruda, Lenvima, gastroesophageal cancer, clinical trial, survival endpoints, progression-free survival, overall survival
Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda
Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns
Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials
Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial
Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions
Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions
BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance
BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry
Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance
Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive